MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1530/eje-21-0239

Медицинская библиотека · European journal of endocrinology · 2021

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.

Fleseriu Maria, Führer-Sakel Dagmar, van der Lely Aart J, De Marinis Laura, Brue Thierry, van der Lans-Bussemaker Joli, Hey-Hadavi Judith, Camacho-Hubner Cecilia, Wajnrajch Michael P, Valluri Srinivas Rao, Palladino Andrew Anthony, Gomez Roy, Salvatori Roberto

Историческая статьяСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVE

To report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY.

DESIGN

Global (15 countries), multicentre, non-interventional study (2004-2017).

METHODS

The complete ACROSTUDY cohort comprised patients with acromegaly, who were being treated with pegvisomant (PEGV) prior to the study or at enrolment. The main endpoints were long-term safety (comorbidities, adverse events (AEs), pituitary tumour volumes, liver tests) and efficacy (IGF1 changes).

RESULTS

Patients (n = 2221) were treated with PEGV for a median of 9.3 years (range, 0-20.8 years) and followed up for a median of 7.4 years (range, 0-13.9 years). Before PEGV, 96.3% had received other acromegaly treatments (surgery/radiotherapy/medications). Before PEGV treatment, 87.2% of patients reported comorbidities. During ACROSTUDY, 5567 AEs were reported in 56.5% of patients and of these 613 were considered treatment-related (in 16.5% of patients) and led to drug withdrawal in 1.3%. Pituitary imaging showed a tumour size increase in 7.1% of patients; the majority (71.1%) reported no changes. Abnormal AST or ALT liver tests occurred in 3.2% of patients. IGF1 normalization rate improved over time, increasing from 11.4% at PEGV start to 53.7% at year 1, and reaching 75.4% at year 10 with the use of ≥30 mg PEGV/day in an increasing proportion of patients.

CONCLUSION

This comprehensive review of the complete cohort in ACROSTUDY confirmed the overall favourable benefit-to-risk profile and high efficacy of PEGV as mono- and combination therapy in patients with an aggressive course/uncontrolled/active acromegaly requiring long-term medical therapy for control.

Для цитирования: Fleseriu Maria, Führer-Sakel Dagmar, van der Lely Aart J, De Marinis Laura, Brue Thierry, van der Lans-Bussemaker Joli, Hey-Hadavi Judith, Camacho-Hubner Cecilia, Wajnrajch Michael P, Valluri Srinivas Rao, Palladino Andrew Anthony, Gomez Roy, Salvatori Roberto. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.. European journal of endocrinology. 2021. DOI: 10.1530/eje-21-0239.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.